The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI)

Ombretta Annibali; Stefan Hohaus; Francesco Marchesi; Maria Cantonetti; Alice Di Rocco; Valeria Tomarchio; Arianna Di Napoli; Sabrina Pelliccia; Roberta Battistini; Paola Anticoli Borza; Elisabetta Abruzzese; Natalia Cenfra; Alessandro Andriani; Cristiano Tesei; Eleonora Alma; Francesca Palombi; Livio Pupo; Luigi Petrucci; Marco Becilli; Elena Maiolo; Silvia Bellesi; Annarosa Cuccaro; Francesco D'Alo'; Maria Christina Cox

doi:10.1080/10428194.2019.1633628

The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI)

Ombretta Annibali, Stefan Hohaus, Francesco Marchesi, Maria Cantonetti, Alice Di Rocco, Valeria Tomarchio, Arianna Di Napoli, Sabrina Pelliccia, Roberta Battistini, Paola Anticoli Borza, Elisabetta Abruzzese, Natalia Cenfra, Alessandro Andriani, Cristiano Tesei, Eleonora Alma, Francesca Palombi, Livio Pupo, Luigi Petrucci, Marco Becilli, Elena MaioloSilvia Bellesi, Annarosa Cuccaro, Francesco D'Alo', Maria Christina Cox

Risultato della ricerca: Contributo in rivista › Abstract

8 Citazioni (Scopus)

Abstract

In solid tumors and lymphomas, the neutrophil/lymphocyte (N/L) ratio at diagnosis has been shown to be a prognostic factor. The aim of our study was to validate the originally reported N/L ratio cut-point of 3.5 in patients with diffuse large B-cell lymphoma (DLBCL) registered in an Italian real-life database. The prognostic role of the N/L ratio at diagnosis on event-free survival (EFS) and overall survival (OS) was assessed in 505 patients with DLBCL. Patients with an N/L ratio <3.5 (n = 249) had a 4-year EFS probability of 76% and OS probability of 86%, significantly higher than the 4 year EFS rate of 48% and OS rate of 64% in patients with N/L ratio ≥3.5 (n = 256, both p<.0001). The N/L ratio was an independent prognostic factor in the multivariate analysis including the IPI score, and could separate patients with a low/intermediate risk IPI (IPI <3).

Lingua originale	English
pagine (da-a)	1-9-9
Rivista	LEUKEMIA & LYMPHOMA
DOI	https://doi.org/10.1080/10428194.2019.1633628
Stato di pubblicazione	Pubblicato - 2019

Keywords

DLBCL
N/L ratio
R-CHOP
cancer
lymphoma

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1080/10428194.2019.1633628

Altri file e collegamenti

Link a IRIS PubliCatt

Fingerprint

Entra nei temi di ricerca di 'The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI)'. Insieme formano una fingerprint unica.

Cita questo

Annibali, O., Hohaus, S., Marchesi, F., Cantonetti, M., Di Rocco, A., Tomarchio, V., Di Napoli, A., Pelliccia, S., Battistini, R., Anticoli Borza, P., Abruzzese, E., Cenfra, N., Andriani, A., Tesei, C., Alma, E., Palombi, F., Pupo, L., Petrucci, L., Becilli, M., ... Cox, M. C. (2019). The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI). LEUKEMIA & LYMPHOMA, 1-9-9. https://doi.org/10.1080/10428194.2019.1633628

@article{412200a541124d678013ce43320d0cb5,

title = "The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network {\textquoteleft}Rete Ematologica del Lazio per i Linfomi{\textquoteright} (RELLI)",

abstract = "In solid tumors and lymphomas, the neutrophil/lymphocyte (N/L) ratio at diagnosis has been shown to be a prognostic factor. The aim of our study was to validate the originally reported N/L ratio cut-point of 3.5 in patients with diffuse large B-cell lymphoma (DLBCL) registered in an Italian real-life database. The prognostic role of the N/L ratio at diagnosis on event-free survival (EFS) and overall survival (OS) was assessed in 505 patients with DLBCL. Patients with an N/L ratio <3.5 (n = 249) had a 4-year EFS probability of 76% and OS probability of 86%, significantly higher than the 4 year EFS rate of 48% and OS rate of 64% in patients with N/L ratio ≥3.5 (n = 256, both p<.0001). The N/L ratio was an independent prognostic factor in the multivariate analysis including the IPI score, and could separate patients with a low/intermediate risk IPI (IPI <3).",

keywords = "DLBCL, N/L ratio, R-CHOP, cancer, lymphoma, DLBCL, N/L ratio, R-CHOP, cancer, lymphoma",

author = "Ombretta Annibali and Stefan Hohaus and Francesco Marchesi and Maria Cantonetti and {Di Rocco}, Alice and Valeria Tomarchio and {Di Napoli}, Arianna and Sabrina Pelliccia and Roberta Battistini and {Anticoli Borza}, Paola and Elisabetta Abruzzese and Natalia Cenfra and Alessandro Andriani and Cristiano Tesei and Eleonora Alma and Francesca Palombi and Livio Pupo and Luigi Petrucci and Marco Becilli and Elena Maiolo and Silvia Bellesi and Annarosa Cuccaro and Francesco D'Alo' and Cox, {Maria Christina}",

year = "2019",

doi = "10.1080/10428194.2019.1633628",

language = "English",

pages = "1--9--9",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor & Francis Limited:Rankine Road, Basingstoke RG24 8PR United Kingdom:011 44 1256 813035, EMAIL: madeline.sims@tandf.co.uk, info@tandf.co.uk, INTERNET: http://www.tandf.co.uk, Fax: 011 44 1256 330245",

}

Annibali, O, Hohaus, S, Marchesi, F, Cantonetti, M, Di Rocco, A, Tomarchio, V, Di Napoli, A, Pelliccia, S, Battistini, R, Anticoli Borza, P, Abruzzese, E, Cenfra, N, Andriani, A, Tesei, C, Alma, E, Palombi, F, Pupo, L, Petrucci, L, Becilli, M, Maiolo, E, Bellesi, S, Cuccaro, A, D'Alo', F & Cox, MC 2019, 'The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI)', LEUKEMIA & LYMPHOMA, pagg. 1-9-9. https://doi.org/10.1080/10428194.2019.1633628

The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI). / Annibali, Ombretta; Hohaus, Stefan; Marchesi, Francesco et al.

In: LEUKEMIA & LYMPHOMA, 2019, pag. 1-9-9.

Risultato della ricerca: Contributo in rivista › Abstract

TY - JOUR

T1 - The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI)

AU - Annibali, Ombretta

AU - Hohaus, Stefan

AU - Marchesi, Francesco

AU - Cantonetti, Maria

AU - Di Rocco, Alice

AU - Tomarchio, Valeria

AU - Di Napoli, Arianna

AU - Pelliccia, Sabrina

AU - Battistini, Roberta

AU - Anticoli Borza, Paola

AU - Abruzzese, Elisabetta

AU - Cenfra, Natalia

AU - Andriani, Alessandro

AU - Tesei, Cristiano

AU - Alma, Eleonora

AU - Palombi, Francesca

AU - Pupo, Livio

AU - Petrucci, Luigi

AU - Becilli, Marco

AU - Maiolo, Elena

AU - Bellesi, Silvia

AU - Cuccaro, Annarosa

AU - D'Alo', Francesco

AU - Cox, Maria Christina

PY - 2019

Y1 - 2019

N2 - In solid tumors and lymphomas, the neutrophil/lymphocyte (N/L) ratio at diagnosis has been shown to be a prognostic factor. The aim of our study was to validate the originally reported N/L ratio cut-point of 3.5 in patients with diffuse large B-cell lymphoma (DLBCL) registered in an Italian real-life database. The prognostic role of the N/L ratio at diagnosis on event-free survival (EFS) and overall survival (OS) was assessed in 505 patients with DLBCL. Patients with an N/L ratio <3.5 (n = 249) had a 4-year EFS probability of 76% and OS probability of 86%, significantly higher than the 4 year EFS rate of 48% and OS rate of 64% in patients with N/L ratio ≥3.5 (n = 256, both p<.0001). The N/L ratio was an independent prognostic factor in the multivariate analysis including the IPI score, and could separate patients with a low/intermediate risk IPI (IPI <3).

AB - In solid tumors and lymphomas, the neutrophil/lymphocyte (N/L) ratio at diagnosis has been shown to be a prognostic factor. The aim of our study was to validate the originally reported N/L ratio cut-point of 3.5 in patients with diffuse large B-cell lymphoma (DLBCL) registered in an Italian real-life database. The prognostic role of the N/L ratio at diagnosis on event-free survival (EFS) and overall survival (OS) was assessed in 505 patients with DLBCL. Patients with an N/L ratio <3.5 (n = 249) had a 4-year EFS probability of 76% and OS probability of 86%, significantly higher than the 4 year EFS rate of 48% and OS rate of 64% in patients with N/L ratio ≥3.5 (n = 256, both p<.0001). The N/L ratio was an independent prognostic factor in the multivariate analysis including the IPI score, and could separate patients with a low/intermediate risk IPI (IPI <3).

KW - DLBCL

KW - N/L ratio

KW - R-CHOP

KW - cancer

KW - lymphoma

KW - DLBCL

KW - N/L ratio

KW - R-CHOP

KW - cancer

KW - lymphoma

UR - http://hdl.handle.net/10807/141174

U2 - 10.1080/10428194.2019.1633628

DO - 10.1080/10428194.2019.1633628

M3 - Meeting Abstract

SN - 1042-8194

SP - 1-9-9

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

ER -

Annibali O, Hohaus S, Marchesi F, Cantonetti M, Di Rocco A, Tomarchio V et al. The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI). LEUKEMIA & LYMPHOMA. 2019;1-9-9. doi: 10.1080/10428194.2019.1633628